Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
Although there have been many improvements in prognosis for patients with cancer, anticancer therapies are burdened by the risk of cardiovascular toxicity. Heart failure is one of the most dramatic clinical expressions of cardiotoxicity, and it may occur acutely or appear years after treatment. This...
Guardado en:
Autores principales: | Alessandra Cuomo, Alessio Rodolico, Amalia Galdieri, Michele Russo, Giacomo Campi, Riccardo Franco, Dalila Bruno, Luisa Aran, Antonio Carannante, Umberto Attanasio, Carlo G Tocchetti, Gilda Varricchi, Valentina Mercurio |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/350633c3d3f44e04b7903c622d9e8c1e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
por: Martins,Sandro José, et al.
Publicado: (2012) -
Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
por: Giulia Bacchiani, et al.
Publicado: (2017) -
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity
por: Himangshu Sonowal, et al.
Publicado: (2017) -
Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Muhammad Mustafa Alhussein, MD, et al.
Publicado: (2021) -
Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
por: Gabriel Vorobiof, et al.
Publicado: (2017)